By InvitationPhase 1/2

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1

China12 participantsStarted 2023-02-16

Plain-language summary

The purpose of this trial is to evaluate safety and efficacy of intravenous delivery of EXG001-307 as a treatment of spinal muscular atrophy Type 1 (SMN1).

Who can participate

Age range1 Day – 180 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. SMA was diagnosed by a bilaterally allelic SMN1 mutation (deletion or point mutation) gene with 2 copies of the SMN2 gene.
✓. On the day of dosing, the subject ' s age did not exceed postnatal Day 180.
✓. The clinical history and signs were consistent with type 1 SMA manifestations, i.e. hypotonia, delayed motor function development, poor head control, round shoulder posture, and joint hypermobility.
✓. The subject's legal guardian understands the purpose, possible risks and interests of the study, agrees to participate in the study, completes all study procedures, tests and visits, and voluntarily signs the informed consent form.
✓. During the study, the subject's legal guardian was willing to perform standard treatment requirements such as nasogastric feeding, noninvasive mechanical ventilation, and expectoration machine as recommended by the investigator.

Exclusion criteria

✕. Gestational age at birth was less than 35 weeks (245 days).
✕. At screening, the subject had an oxygen saturation \< 96% while awake or sleeping and did not receive any supplemental oxygen or respiratory support.
✕. Requirement of invasive ventilation or tracheotomy, or current use of noninvasive ventilatory support for an average of ≥ 16 hours/day.
✕. Weighed below the 3rd percentile by age according to the WHO Child Growth Criteria (WHO 2009).
✕. Before administration, if the subject has not received or delayed vaccination according to the current month-old national vaccination plan, it will significantly affect the safety of the subject as assessed by the investigator and the medical manager of the project team;
✕. Active viral infections (including HIV, COVID-19, hepatitis B or C seropositivity, torch virus, Epstein-Barr virus, and syphilis).
✕. Serious non-respiratory disease within 2 weeks prior to screening.
✕. Upper respiratory tract infection or lower respiratory tract infection within 4 weeks prior to screening.

What they're measuring

To evaluate the safety and tolerability of EXG001-307 following a single intravenous infusion

Timeframe: During each visit

Trial details

NCT IDNCT05614531

SponsorGuangzhou Jiayin Biotech Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-08

View on ClinicalTrials.gov More Spinal Muscular Atrophy Type I trials